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ABSTRACT
This is a report of an unintended application of MR-HIFU therapy of uterine fibroids (UFs) in a woman
in early pregnancy and should be treated as the first description of such an event.
A 37-year-old nullipara with confirmed UFs, who suffered from excessive uterine bleeding and dys-
menorrhea, was qualified for MR-HIFU therapy to reduce UF-related symptoms. The procedure took
place 2months later. No complications occurred and the patient was discharged home in good overall
condition. About 5weeks after the procedure the patient was diagnosed with viable intrauterine preg-
nancy. Basing on early pregnancy ultrasound it was calculated that at the time of MR-HIFU procedure
the patient was about 10 (þ/ 3days) days after the conception. Later, the pregnancy was uncompli-
cated and she gave birth to a healthy neonate. Physical examinations did not reveal any abnormalities
in her child. Symptoms associated with UFs significantly decreased after the therapy and pregnancy.
Despite the fact that the pregnancy being subjected to MR-HIFU treatment had further uncomplicated
course, the presented case indicates that counseling/management in women at reproductive age
should be standardized to avoid unknown consequences of such unrecommended procedures for the
fetus. According to current standards MR-HIFU procedures to treat UFs should never be performed
without a negative pregnancy test.
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Uterine fibroids (UFs) are common, benign tumors originat-
ing from the myometrium [1]. The growth and location are
the main factors that determine if a tumor leads to symp-
toms which may include abnormal uterine bleeding, anemia,
pelvic and abdominal pain, infertility and a variety of obstet-
ric complications [2].
For many years, surgery remained the method of choice
in UF management [2]. Nowadays, there is a trend to make
the treatment less invasive and individually tailored to the
patient’s specific situation [3,4]. Women with symptomatic
UFs who wish to conceive search for methods that preserve
full ability to reproduce [5]. One of the possible solutions to
this problem is the use of ultrasound beam. Magnetic reson-
ance-guided high-intensity focused ultrasound (MR-HIFU) is a
quickly developing technology with a potential application in
various clinical indications, including UFs [6]. As for now this
method is still not recommended for women wishing to pre-
serve fertility, except for selected countries including the
USA. However, this point of view is significantly changing by
a growing quantity of available data [7,8].
At this point it should be strongly emphasized that we
never perform a MR-HIFU procedure to treat UFs without a
negative pregnancy test. A pregnancy is considered as an
absolute contraindication to the procedure, and there are no
data regarding the safety of MR-HIFU. We present an event
associated with the application of MR-HIFU for the treatment
of fibroids in a woman with undiagnosed early intrauter-
ine pregnancy.
Case report
We present a case of a 37-year-old nullipara with confirmed
UFs who suffered from excessive uterine bleeding and dys-
menorrhea. The patient was admitted to our department for
MR-HIFU therapy as she wanted to reduce the UF-related
symptoms and eventually conceive in the future. The patient
refused surgery and did not want to use any kind of avail-
able hormonal treatment.
Transvaginal ultrasound scan and magnetic resonance
imaging (MRI) (Philips Ingenia 3.0 T system, Philips,
Amsterdam, Netherlands) performed during the hospitalization
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confirmed the presence of 2 UFs. The first one, about
21 20 17mm in size (volume ¼ 3.84 cm3), was a type 3 UF
according to the FIGO classification [9]. The tumor contacted
the endometrium directly which could be the reason for clin-
ical symptoms (Figure 1). The second tumor coming out of
the posterior wall had a diameter of about 10mm and was a
FIGO type 4 UF. The smaller tumor was considered as poten-
tially asymptomatic [9]. MRI signal intensity of both lesions
corresponded to type I according to Funaki et al. (2007) [10].
After counseling the patient was qualified for MR-HIFU pro-
cedure which was scheduled 2months later.
The patient was admitted to the hospital on the indicated
day - it was the 25th day of the menstrual cycle. Her men-
strual cycles were about the same length every month,
occurring every 26–28 days. The patient performed standard
urine pregnancy test according to the routine procedure –
the test was undoubtedly negative, as a result of which MR-
HIFU procedure was initiated. MR-HIFU Sonalleve (Philips,
Amsterdam, Netherlands) device, which integrates an MRI
scanner, was used. The duration of the whole procedure was
about 120min with the sonification time of 66min. During
MR-HIFU non-perfused volume (NPV) equaled 70%, the max-
imum power was 180W and the temperature reached 62
degrees Celsius (Figures 2 and 3). The procedure took place
without any complications and the patient was discharged
home in a good general condition with the recommendation
of presenting for a follow-up visit in 3 months’ time. Due to
the prolonging lack of menstrual period the patient came to
an earlier check at the outpatient clinic in her place of resi-
dence. The physician confirmed the presence of a viable
pregnancy (8/9weeks of gestation - which corresponded to
the gestational age from the last menstrual period). The data
allowed to calculate that at the time of MR-HIFU procedure
the patient was about 10 days after conception according to
the first ultrasound, and between 8 and 12 days after con-
ception basing on the date of the last menstruation, which
would suggest that the pregnancy may have already nested
within the uterine cavity.
The later part of the pregnancy was uncomplicated, the
fetus grew normally and the UF did not cause any symptoms
(Figure 4). The patient was initially scheduled for a vaginal
delivery. However, due to a suspicion of macrosomia she
was re-qualified for a cesarean section. The patient gave
birth to a healthy neonate (4135 grams), the first and subse-
quent physical examinations did not reveal any abnormalities
in the child, the UF was not removed during the surgery.
Due to the lack of obstetric complications and the reduction
of UF-related symptoms, the patient was not subjected to
further treatment. The case report timeline is available in
Figure 5.
Discussion
According to the extensive research through the available
databases this is the first described case of a woman with
UFs who underwent MR-HIFU procedure after conception
and gave birth to a healthy neonate.
MR-HIFU method is focused on optimal clinical efficacy,
quick recovery and high-grade safety [11]. Side effects are
uncommon in patients who decided to choose this therapy
[12]. According to available data the majority of women in
whom MR-HIFU was performed reported a significant reduc-
tion in UF-related clinical symptoms and no need of re-inter-
vention [7,12]. Even with those highly successful results MR-
HIFU still does not find its place in general UF treatment
guidelines and is not recommended for women wishing to
conceive [13], probably due to the lack of extensive high
quality data about the safety of the procedure for further
pregnancy. However, in recent years the trend to strictly pro-
hibit this form of treatment has been slowing down. Some
authors stated that such a form of therapy should not be
treated as a contraindication to future pregnancies [7]. A
recent systematic review revealed that pregnancies after this
Figure 1. Transvaginal ultrasound scan 2months before MR-HIFU procedure. Uterine fibroid in the anterior wall in direct contact with the endometrium.
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form of treatment had low complication rates and the major
negative effect was first trimester bleeding. However, further
studies should be performed to obtain additional data [14].
Very recent studies demonstrated that pregnancies after MR-
HIFU treatment have favorable outcomes and no strictly
related symptoms occur in the perinatal period [8,15].
Figure 2. The uterus and the uterine fibroid during MR-HIFU procedure. Thermometry guidance during the thermal ablation.
Figure 3. MRI scan of the lower abdomen and pelvis. (A) MR-HIFU qualification MRI scan. (B) MRI scan after the MR-HIFU procedure – visible tumor necrosis.
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Vaginal delivery after this kind of therapy appears to be safe
as well [8].
The presented case shows that despite the use of a
strong ultrasound beam on already existing pregnancy, there
were no adverse outcomes. In our opinion, the use of MR-
HIFU in case of an already confirmed pregnancy is and will
be absolutely contraindicated, and this case should be
treated as an unexpected and unrecommended event. Our
case showed that urine pregnancy test was insufficient to
qualify the patient for the procedure during late secretory
phase. Therefore, we suggest to perform an additional blood
test to exclude pregnancy in such cases (e.g. urine with sub-
sequent blood test at a different stage of the cycle).
However, the majority of UF patients have abnormal uterine
bleeding so it might be difficult to tell when the normal
cycle occurs. Guidelines for the safe performance of the pro-
cedure in women at reproductive age should be developed.
Furthermore, detailed counseling should be conducted
including the recommendation to refrain from sexual inter-
courses without contraception if surgery is planned in the
luteal phase. If effective contraception cannot be obtained,
another solution may be the use of MR-HIFU only during the
first phase of the cycle. Our case shows that the ultrasound
used in MR-HIFU is focused strictly on the structure being
treated, probably without large damage the adjacent fragile
tissues (the endometrium, early pregnancy). Despite the
uncomplicated pregnancy after the event, this case report
does not provide a prognostic value for other similar events,
and further efforts should be focused on avoiding the risk
for the fetus.
Conclusion
In the presented case, the result of pregnancy being sub-
jected to MR-HIFU treatment was favorable.
MR-HIFU procedure to treat UFs should never be per-
formed without a negative pregnancy test. However, more
detailed guidelines for a safe use of MR-HIFU and additional
tests in women at reproductive age are necessary, e.g. blood
pregnancy test about 1week before the procedure and urine
pregnancy test or the second blood test on the day of the
treatment. A written statement of sexual abstinence over the
whole period of the procedure should be considered
as necessary.
In our opinion MR-HIFU offers an attractive alternative to
traditional methods of UF treatment.
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